MBRX Stock Analysis: Buy, Sell, or Hold?
MBRX - Moleculin Biotech, Inc.
$0.43
0.02 (6.25%)
▲
5d:
-80.59%
30d:
-83.9%
90d:
-83.07%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
6d
Get Alerted When MBRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: MBRX is down 80.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: MBRX is down 80.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: MBRX is currently trading at $0.42, which is considered oversold relative to its 30-day fair value range of $1.49 to $2.88.
Technical Outlook: Technically, MBRX is showing sideways momentum. Immediate support is located at $0.16, while resistance sits at $2.26. The stock is showing strong short-term momentum, up 6.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.00 (+4841.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MBRX is showing sideways momentum. Immediate support is located at $0.16, while resistance sits at $2.26. The stock is showing strong short-term momentum, up 6.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.00 (+4841.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.49 -
$2.88
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.2%)
- BULLISH: Trading 4841.2% below Wall St target ($21.00)
- WARNING: Recommendation downgraded due to -80.6% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.49 -
$2.88
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.16
Resistance Level
$2.26
Current Trend
Sideways
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.11
Wall Street Target
$21.00
(+4841.2%)
Share & Embed Analysis
Last updated: August 04, 2026 5:28 AM ET
Data refreshes hourly during market hours. Next update: 6:28 AM
Data refreshes hourly during market hours. Next update: 6:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MBRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 54 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 59 HOLD |
